



BioAegis Therapeutics Receives US Patent Protection for the Therapeutic Uses of Plasma Gelsolin in Renal Failure

MORRISTOWN, NJ, (BIOAEGIS THERAPEUTICS) April 30, 2019 BioAegis Therapeutics Inc., a privately held biotechnology company commercializing recombinant human plasma gelsolin (pGSN) announced today that the United States Patent Office has issued a patent for the Use of Plasma Gelsolin to Diagnose and Treat Renal Failure.

About Plasma Gelsolin

The highly abundant endogenous plasma protein, pGSN, harnesses the innate immune system to modulate the inflammatory response as well as boost the capacity of immune cells to fight infection. Decreased plasma gelsolin levels at presentation are found in patients with diverse infectious and non-infectious inflammatory diseases, who are at high risk for developing serious complications.

Renal Disease

According to the **Center for Health Statistics**, over 5.1 million people in the United States have been diagnosed with kidney disease representing 2.1% of the adult population.: 50,046. In 2016 there were approximately 2,744,248 registered deaths from nephritis, nephrotic syndrome and nephrosis (kidney disease) making it the 9th leading cause of mortality.

Plasma Gelsolin and Kidney Disease

Low systemic levels of plasma gelsolin is an independent predictor of one year mortality from either infectious or cardiovascular causes in patients on renal dialysis.

About BioAegis Therapeutics

BioAegis Therapeutics was founded by a group of highly experienced pharmaceutical and financial executives. Its mission is to harness the body's innate immune system to address serious outcomes in diseases driven by inflammation and infection.

This press release contains express or implied forward-looking statements, which are based on current expectations of management. These statements relate to, among other things, our expectations regarding management's plans, objectives, and strategies. These statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward- looking statements. BioAegis assumes no obligation to update any forward-looking statements appearing in this press release in the event of changing circumstances or otherwise, and such statements are current only as of the date they are made.

For further information:

Steven Cordovano, 203-952-6373

Email: scordovano@bioaegistx.com

www.bioaegistx.com